Epilepsia
El cannabis, en particular el cannabidiol (CBD), ha demostrado un potencial significativo en el manejo de la epilepsia, especialmente en formas de la enfermedad resistentes al tratamiento. El CBD interactúa con el sistema endocannabinoide, modulando la actividad neuronal y reduciendo la hiperexcitabilidad en el cerebro, que es un factor clave en las convulsiones (Devinsky et al., 2014). Los ensayos clínicos han demostrado que el CBD puede reducir significativamente la frecuencia de las convulsiones, ofreciendo una posible línea de vida para pacientes que no responden a los fármacos antiepilépticos convencionales (Thiele et al., 2018).
La Administración de Alimentos y Medicamentos de los Estados Unidos (FDA) ha aprobado Epidiolex, un medicamento a base de CBD, para el tratamiento de síndromes epilépticos raros como el síndrome de Dravet y el síndrome de Lennox-Gastaut, lo que resalta su eficacia y perfil de seguridad (FDA, 2018).
Los estudios sugieren que el CBD no solo reduce la gravedad de las convulsiones, sino que también mejora la calidad de vida al disminuir síntomas asociados como la ansiedad y los trastornos del sueño (Szaflarski et al., 2018).
Si bien el potencial terapéutico del CBD es convincente, el THC —un cannabinoide psicoactivo— debe abordarse con cautela en el manejo de la epilepsia debido a su potencial para exacerbar las convulsiones en algunos casos. A medida que avanza la investigación, los tratamientos derivados del cannabis podrían desempeñar un papel cada vez más importante en la atención personalizada de la epilepsia.
References
- 1. Devinsky, O., Cilio, M. R., Cross, H., et al. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 55(6), 791-802.
- 2. FDA (2018). FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. U.S. Food and Drug Administration.
- 3. Szaflarski, J. P., Bebin, E. M., Comi, A. M., et al. (2018). Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia, 59(8), 1540-1548.
- 4. Thiele, E. A., Marsh, E. D., French, J. A., et al. (2018). Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomized, double-blind, placebo-controlled phase 3 trial. The Lancet, 391(10125), 1085-1096.
- 5. Devinsky, O., Patel, A. D., Cross, J. H., et al. (2017). Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. The New England Journal of Medicine, 376(21), 2011-2020.
Servicios relacionados
Cannabis has garnered attention as a potential adjunct therapy for bipolar disorder, offering therapeutic benefits when used…
Cannabis has emerged as a complementary option in managing cancer-related symptoms, providing…
Cannabis has shown promise as a therapeutic option for managing Crohn’s disease, a chronic…
Cannabis has gained recognition as a potential therapy for managing chronic pain, offering relief…
Cannabis is being explored as a potential adjunct therapy for managing depression, offering…
Cannabis has been explored as a potential treatment for glaucoma, a condition characterized…
Cannabis is being studied as a potential therapy for managing pain associated with gout, a form of…
Cannabis is being explored as a complementary therapy for managing symptoms associated with….
Cannabis has demonstrated potential in improving the quality of life for individuals living with..
Cannabis has been studied for its potential to help manage hypertension (high blood pressure), a…
Cannabis has gained as a potential treatment for Irritable Bowel Syndrome (IBS), a gastrointestinal disorder…
Cannabis has gained attention as a potential treatment for insomnia, a common sleep disorder..
Cannabis has shown potential in the treatment of migraines, a neurological condition characterized…
Cannabis has shown potential as a therapeutic option for managing symptons of multiple sclerosis (MS), a chronic…